As more health systems seek to make use of the cost savings associated with biosimilars, data continue to accrue to support switching patients to these products. One recent paper, published in The Journal of Clinical Medicine, reported that, after a switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), patients with ankylosing spondylitis (AS) who switched to the biosimilar remained in remission at 18 months post-switch.
As more health systems seek to make use of the cost savings associated with biosimilars, data continue to accrue to support switching patients to these products. One recent paper, published in The Journal of Clinical Medicine, reported that, after a switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), patients with ankylosing spondylitis (AS) who switched to the biosimilar remained in remission at 18 months post-switch.
The study, conducted at a single center in Greece, included 88 infliximab-treated patients with AS who were in clinical remission. All patients were naïve to previous biologics before starting infliximab, and all were provided with education about the switch. In total, 45 patients were switched to the biosimilar, while 43 patients continued to receive the reference infliximab. Clinical, laboratory, and demographic parameters were similar between the 2 groups.
At the end of the 18 months of follow-up, write the investigators, all patients in both groups remained in clinical remission as determined by the Bath Ankylosing Spondylitis Activity Index and the Ankylosing Spondylitis Activity Score using C-reactive protein, and no significant adverse events or comorbidities were observed in either group.
In total, 4 patients who had switched to the biosimilar reported what the investigators call “subjective complaints,” including somnolence and headache. These patients were deemed to have nocebo effects and were switched back to the reference, and 1 was switched to a different agent, all with good results. In the reference group, 2 patients had respiratory tract infections and 1 patient experience a disease flare. These patients were also switched to a different agent and had good results.
“Our findings are in line with the PLANETAS study despite the fact that they used different tools in assessing disease activity,” write the authors, who add that the success of the switch may be linked with patient education and its ability to reduce the nocebo effect.
While the study is limited by the small number of patients, it offers, according to the authors, the longest comparative data on a switch to biosimilar infliximab in patients with AS.
Reference
Kaltsonoudis, Pelechas E, Voulgari PV, Drososo AA. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: an 18-month comparative open-label study [published online July 2, 2019]. J Clin Med.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.